# Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

> **NCT01629082** · PHASE1 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 4 (actual)

## Conditions studied

- Myeldysplastic Syndrome (MDS)
- Chronic Myelomonocytic Leukemia
- Bone Marrow Diseases
- Neutropenia
- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT01629082
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-06
- **Primary completion:** 2015-10-27
- **Final completion:** 2018-06-27
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2019-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01629082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01629082, "Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01629082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*